Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results